- Home
- USEG vs CNTB Comparison
USEG vs CNTB Comparison
Compare USEG & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- CNTB
- Stock Information
- Founded
- USEG 1966
- CNTB 2012
- Country
- USEG United States
- CNTB United States
- Employees
- USEG N/A
- CNTB N/A
- Industry
- USEG Oil & Gas Production
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- USEG Energy
- CNTB Health Care
- Exchange
- USEG Nasdaq
- CNTB Nasdaq
- Market Cap
- USEG 68.6M
- CNTB 55.2M
- IPO Year
- USEG N/A
- CNTB 2021
- Fundamental
- Price
- USEG $1.95
- CNTB $0.87
- Analyst Decision
- USEG Strong Buy
- CNTB Strong Buy
- Analyst Count
- USEG 2
- CNTB 1
- Target Price
- USEG $2.75
- CNTB $8.00
- AVG Volume (30 Days)
- USEG 4.2M
- CNTB 23.0K
- Earning Date
- USEG 03-25-2025
- CNTB 04-15-2025
- Dividend Yield
- USEG N/A
- CNTB N/A
- EPS Growth
- USEG N/A
- CNTB N/A
- EPS
- USEG N/A
- CNTB N/A
- Revenue
- USEG $22,257,000.00
- CNTB $24,116,000.00
- Revenue This Year
- USEG N/A
- CNTB N/A
- Revenue Next Year
- USEG $12.17
- CNTB $63.90
- P/E Ratio
- USEG N/A
- CNTB N/A
- Revenue Growth
- USEG N/A
- CNTB N/A
- 52 Week Low
- USEG $0.81
- CNTB $0.77
- 52 Week High
- USEG $6.40
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- USEG 43.97
- CNTB 37.85
- Support Level
- USEG $2.03
- CNTB $0.91
- Resistance Level
- USEG $2.17
- CNTB $0.95
- Average True Range (ATR)
- USEG 0.22
- CNTB 0.08
- MACD
- USEG -0.05
- CNTB -0.01
- Stochastic Oscillator
- USEG 0.00
- CNTB 27.95
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.